Safety evaluation of meso-zeaxanthin

The findings of no acute toxicity, no mutagenic effects and no harmful effects in hematology, clinical chemistry and histopathology in this safety assessment indicate that the use of meso-zeaxanthin is safe at dose of 300 mg/kg bw/day in rats. The no-observed-adverse-effect-level (NOAEL) of meso-zeaxanthin in rats is 300 mg/kg bw/day when administered orally for 13 consecutive weeks. Application of a 100-fold safety factor to the rat study, the suggested ADI value is 3 mg/kg bw/day. Hence to further confirm these findings of no toxicity in the application of human consumption, a longer term animal study and or year-long human clinical trial safety evaluation of meso-zeaxanthin would be suggested as dietary supplements and for prolonged use.

Posted in Latest News


Introduction to the relationship between Macular Pigment and Glare.

Here is an introduction on the role macular pigment can play in improving visual performance under glare conditions. Scientific research has shown that another positive effect of increasing one's macular pigment is that it can facilitate in decreasing an individual's sensitivity to glare and also decrease their recovery time when blinded by glare.

Posted in Latest News


Vitamins E, C no help against vision disorder

By Amy Norton, Reuters

NEW YORK (Reuters Health) - Taking vitamins E and C may do nothing to protect aging eyes from macular degeneration -- the leading cause of vision loss in older adults, a new clinical trial finds.
Researchers had been hoping the vitamins, both antioxidants, could shield against the tissue erosion that occurs in macular degeneration. The condition involves damage to the center of the retina, which makes it hard to see fine details.

Studies have found that people who get more antioxidants in their diet have a lower risk of macular degeneration. But that doesn't rule out other possible diet or lifestyle explanations behind the link.
And so far, clinical trials using vitamin E have come up empty.

Posted in Latest News


Role of Ocular Melanin in Ophthalmic Physiology and Pathology

By Hu, Dan-Ning Simon, John D; Sarna, Tadeusz

ABSTRACT The mammalian eye consists of several layers of pigmented tissues that contain melanin. The eye is a unique organ for pigment cell research because one can isolate and compare melanosomes from different tissues and embryonic origins. Retinal, iris and ciliary pigment epithelial cells are derived from the neural ectoderm, more specifically from the extremity of the embryonic optical cup, which is also the origin of the retina. In contrast, the pigment-generating cells in the choroid and in the stroma of the iris and ciliary body, uveal melanocytes, are developed from the neural crest, the same origin as the melanocytes in skin and hair. This review examines the potential functions of ocular melanin in the human eye. Following a discussion of the role of melanins in the pigment epithelium and uveal melanocytes, three specific topics are explored in detail-photo-screening protective effects, biophysical and biochemical protective effects, and the biologic and photobiologic effects of the two main classes of melanins (generally found as mixtures in ocular melanosomes)- eumelanin and pheomelanin.

Posted in Latest News



Genetic testing can provide early detection of macular degeneration, and possibly save patients’ vision

Larry Anderson of Allenstown has his eyes examined for macular degeneration by Dr. Anthony Correnti at New Hampshire Eye Associates in Manchester.

A leading cause of blindness for those 55 and older that aff ects more than 10 millionAmericans, macular degeneration is caused by deterioration of the central portion ofthe retina, known as the macula, and characterized by loss of central vision.


A FEW YEARS AGO, GaryHermsdorf learned hewas in the early stagesof age-related maculardegeneration.A leading cause of blindnessfor those 55 and older that affectsmore than 10 million Americans,macular degeneration is caused bydeterioration of the central portionof the retina, known as the macula,and characterized by loss of centralvision, according to the AmericanMacular Degeneration Foundation.The disease robbed Hermsdorf’suncle of his vision, but the 66-yearoldHooksett retiree is determinedto avoid the same fate.“Seeing that happen to my uncleand knowing I was starting downthe same road, I would and will doabsolutely anything that will helpme,” he said.Recently, Hermsdorf’s eye doctortold him about a new DNA testfor patients diagnosed with earlyforms of macular degeneration thatidentifi es those most likely to progressto more advanced forms ofvision loss. The test, called MaculaRisk, uses genetics and smokinghistory to identify a patient’s risklevel.New Hampshire Eye Associates,the Manchester practice whereHermsdorf is a patient, beganoffering the test late last year, saidAnthony Correnti, the eye surgeonand retina specialist who treatsHermsdorf. The practice is one ofonly about 500 that offer it nationwide,Correnti said.The prevalence of maculardegeneration among its patientsprompted New Hampshire EyeAssociates to introduce the test,Correnti said. “About 70 percent ofthe patients I see are dealing withsome form of it,” he said.People with early maculardegeneration have no symptomsor vision loss, according to the NationalEye Institute. The hallmarksof the condition are drusen, or fi neyellow deposits under the retina detectable only by an eye exam,Correnti said.Early macular degeneration isone of three stages of the “dry”form of the disease, which is typified by gradual vision loss.“Sometimes the changes happen so slowly that people don’t realizeit until they’ve lost almost all theirvision in one eye,” Correnti said.While 90 percent of those withmacular degeneration suffer fromthe dry form, the disease also hasa “wet” form that occurs whenabnormal blood vessels behind theretina start to grow under the macula,damaging it rapidly by leakingblood and fluid, according to the National Eye Institute.

Posted in EyeSolutions Blog, Latest News


Reach customer service for general questions and comments.

Contact Us